OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Forecast, Price & News

$0.16

+0.01 (+6.62%)

(As of 09/26/2023 ET)

Compare

Today's Range: $0.16
▼
$0.19
50-Day Range: $0.14
▼
$0.28
52-Week Range: $0.14
▼
$3.00

Volume: 73,360 shs
Average Volume: 37,615 shs
Market Capitalization: $1.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Vyant Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 3,005.6% Upside
$5.00 Price Target
Short Interest: Healthy
0.86% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.55
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Vyant Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Vyant Bio has a forecasted upside of 3,005.6% from its current price of $0.16.
Amount of Analyst Coverage
Vyant Bio has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.86% of the outstanding shares of Vyant Bio have been sold short.
Short Interest Ratio / Days to Cover
Vyant Bio has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vyant Bio has recently decreased by 1.09%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Vyant Bio does not currently pay a dividend.
Dividend Growth
Vyant Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VYNT.

3.6

News and Social Media Coverage

News Sentiment
Vyant Bio has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vyant Bio this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Vyant Bio to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vyant Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.56% of the stock of Vyant Bio is held by insiders.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
Vyant Bio has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vyant Bio (OTCMKTS:VYNT) Stock

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

VYNT Price History

30 days | 90 days | 365 days | Advanced Chart

VYNT Stock News Headlines

September 27, 2023 | americanbankingnews.com

Vyant Bio (OTCMKTS:VYNT) Shares Up 7.3%

September 20, 2023 | finance.yahoo.com

Vyant Bio Announces Adjournment of Special Meeting of Stockholders

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 21, 2023 | yahoo.com

Medicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds say

August 21, 2023 | washingtonpost.com

‘Asian glow’ from alcohol isn’t just a discomfort. It’s a severe warning.

August 18, 2023 | msn.com

Gene that vastly increases chance of breast cancer found by scientists

August 17, 2023 | msn.com

The dangerous gene that vastly increases your chance of breast cancer

August 9, 2023 | msn.com

AI Can Find Cancer’s Origin: Study

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

July 18, 2023 | benzinga.com

Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy

July 17, 2023 | bizjournals.com

Vyant Bio enters into deal to sells its microBrain assets for $2.25M

July 17, 2023 | finance.yahoo.com

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

July 6, 2023 | msn.com

Gene editing helped crack a 100-year-old mystery about cancer

July 3, 2023 | msn.com

Certain genetic mutations linked to treatment-resistant breast cancer, new study discovers

July 3, 2023 | msn.com

Testing begins for Orkney cancer gene link

June 29, 2023 | usatoday.com

Are you truly at risk for prostate cancer? Adding genetics may give more accurate PSA tests

June 7, 2023 | msn.com

KHCC presents Cancer Genetics study in leading conference in US

June 6, 2023 | msn.com

DNA sequencing can lead to longer, better lives for cancer patients. But why do so few get it?

June 2, 2023 | msn.com

Endometrial Cancer Warning Signs: What to Look Out For

May 25, 2023 | msn.com

UCLA researchers say genetic mutation could be key to treating fatal brain tumors

May 18, 2023 | msn.com

Junk genes may hold keys to cancer cure, CWRU researchers find

May 16, 2023 | technews.tmcnet.com

New Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision Prevention

May 12, 2023 | proactiveinvestors.com

Vyant Bio to pursue listing on OTC Pink Open Market

May 12, 2023 | finance.yahoo.com

Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration

May 12, 2023 | marketwatch.com

8-K: Vyant Bio, Inc.

May 8, 2023 | washingtonpost.com

Ask a Doctor: Which cancers can be detected through genetic testing?

May 8, 2023 | markets.businessinsider.com

Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care

See More Headlines

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Company Calendar

Last Earnings: 11/11/2021
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:VYNT
CUSIP: N/A
CIK: 1349929
Web: stemonix.com
Phone: (201) 479-1357
Fax: 201-528-9201
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +3,005.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,690,000.00
Net Margins: -3,474.81%
Pretax Margin: -3,281.86%
Return on Equity: -151.82%
Return on Assets: -97.14%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 2.86
Quick Ratio: 2.86

Sales & Book Value

Annual Sales: $670,000.00
Price / Sales: 1.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.69 per share
Price / Book: 0.10

Miscellaneous

Outstanding Shares: 6,330,000
Free Float: 5,724,000
Market Cap: $1.02 million
Optionable: Not Optionable
Beta: 1.79

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Andrew D.C. LaFrence CPA (Age 60)
CPA, Pres, CEO & CFO
Comp: $407.4k

Mr. Yung-Ping Yeh M.B.A. (Age 47)
M.S., P.M.P., Co-Founder & Director
Comp: $22.5k

Key Competitors

View All Competitors

VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYNT shares.
View VYNT analyst ratings or view top-rated stocks.
What is Vyant Bio's stock price forecast for 2023?: 2 Wall Street research analysts have issued twelve-month price objectives for Vyant Bio's shares. Their VYNT share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 3,005.6% from the stock's current price.
View analysts price targets for VYNT or view top-rated stocks among Wall Street analysts.
How have VYNT shares performed in 2023?: Vyant Bio's stock was trading at $0.7025 at the start of the year. Since then, VYNT shares have decreased by 77.1% and is now trading at $0.1610.
View the best growth stocks for 2023 here.
When is Vyant Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VYNT earnings forecast.
How were Vyant Bio's earnings last quarter?: Vyant Bio, Inc. (OTCMKTS:VYNT) posted its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.75). The firm had revenue of $1.51 million for the quarter, compared to analysts' expectations of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%. During the same quarter in the previous year, the firm earned ($2.90) earnings per share.

When did Vyant Bio's stock split?: Shares of Vyant Bio reverse split on the morning of Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What is Vyant Bio's stock symbol?: Vyant Bio trades on the OTCMKTS under the ticker symbol "VYNT."
How do I buy shares of Vyant Bio?: Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vyant Bio's stock price today?: One share of VYNT stock can currently be purchased for approximately $0.16.
How much money does Vyant Bio make?: Vyant Bio (OTCMKTS:VYNT) has a market capitalization of $1.02 million and generates $670,000.00 in revenue each year.
How can I contact Vyant Bio?: Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201.

This page (OTCMKTS:VYNT) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial